182 related articles for article (PubMed ID: 11796365)
1. Use of terbinafine in mouse and rat models of Pneumocystis carinii pneumonia.
Walzer PD; Ashbaugh A
Antimicrob Agents Chemother; 2002 Feb; 46(2):514-6. PubMed ID: 11796365
[TBL] [Abstract][Full Text] [Related]
2. Employment of terbinafine against Pneumocystis carinii infection in rat models.
Contini C; Colombo D; Cultrera R; Prini E; Sechi T; Angelici E; Canipari R
Br J Dermatol; 1996 Jun; 134 Suppl 46():30-2; discussion 40. PubMed ID: 8763466
[TBL] [Abstract][Full Text] [Related]
3. Activity of terbinafine against Pneumocystis carinii in vitro and its efficacy in the treatment of experimental pneumonia.
Contini C; Manganaro M; Romani R; Tzantzoglou S; Poggesi I; Vullo V; Delia S; De Simone C
J Antimicrob Chemother; 1994 Nov; 34(5):727-35. PubMed ID: 7706168
[TBL] [Abstract][Full Text] [Related]
4. Structural changes in rat Pneumocystis carinii surface antigens after terbinafine administration in experimental P. carinii pneumonia.
Contini C; Angelici E; Canipari R
J Antimicrob Chemother; 1999 Feb; 43(2):301-4. PubMed ID: 11252340
[TBL] [Abstract][Full Text] [Related]
5. Immunodeficient and immunosuppressed mice as models to test anti-Pneumocystis carinii drugs.
Walzer PD; Runck J; Steele P; White M; Linke MJ; Sidman CL
Antimicrob Agents Chemother; 1997 Feb; 41(2):251-8. PubMed ID: 9021175
[TBL] [Abstract][Full Text] [Related]
6. Activities of sordarins in experimental models of candidiasis, aspergillosis, and pneumocystosis.
Martinez A; Aviles P; Jimenez E; Caballero J; Gargallo-Viola D
Antimicrob Agents Chemother; 2000 Dec; 44(12):3389-94. PubMed ID: 11083645
[TBL] [Abstract][Full Text] [Related]
7. In vitro selection and in vivo efficacy of piperazine- and alkanediamide-linked bisbenzamidines against Pneumocystis pneumonia in mice.
Cushion MT; Walzer PD; Ashbaugh A; Rebholz S; Brubaker R; Vanden Eynde JJ; Mayence A; Huang TL
Antimicrob Agents Chemother; 2006 Jul; 50(7):2337-43. PubMed ID: 16801410
[TBL] [Abstract][Full Text] [Related]
8. In-vitro activity of terbinafine, atovaquone and co-trimoxazole against Pneumocystis carinii.
Cirioni O; Giacometti A; Balducci M; Burzacchini F; Scalise G
J Antimicrob Chemother; 1995 Oct; 36(4):740-2. PubMed ID: 8591953
[No Abstract] [Full Text] [Related]
9. Trophozoite elimination in a rat model of Pneumocystis carinii pneumonia by clinically achievable plasma deferoxamine concentrations.
Merali S; Chin K; Grady RW; Clarkson AB
Antimicrob Agents Chemother; 1996 May; 40(5):1298-300. PubMed ID: 8723489
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo models of Pneumocystis carinii.
Bartlett MS; Queener SF; Shaw MM; Durant PJ; Lee CH; Smith JW
J Eukaryot Microbiol; 1997; 44(6):51S. PubMed ID: 9508437
[No Abstract] [Full Text] [Related]
11. Inactivity of terbinafine in a rat model of pulmonary aspergillosis.
Schmitt HJ; Andrade J; Edwards F; Niki Y; Bernard E; Armstrong D
Eur J Clin Microbiol Infect Dis; 1990 Nov; 9(11):832-5. PubMed ID: 2128278
[TBL] [Abstract][Full Text] [Related]
12. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly.
Gupta AK; Konnikov N; Lynde CW
J Am Acad Dermatol; 2001 Mar; 44(3):479-84. PubMed ID: 11209118
[TBL] [Abstract][Full Text] [Related]
13. Clinically achievable plasma deferoxamine concentrations eliminate Pneumocystis carinii trophozoites in a rat model.
Merali S; Chin K; Grady RW; Clarkson AB
J Eukaryot Microbiol; 1996; 43(5):52S. PubMed ID: 8822854
[No Abstract] [Full Text] [Related]
14. Novel pentamidine analogs in the treatment of experimental Pneumocystis carinii pneumonia.
Jones SK; Hall JE; Allen MA; Morrison SD; Ohemeng KA; Reddy VV; Geratz JD; Tidwell RR
Antimicrob Agents Chemother; 1990 Jun; 34(6):1026-30. PubMed ID: 2393262
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice.
Ito M; Nozu R; Kuramochi T; Eguchi N; Suzuki S; Hioki K; Itoh T; Ikeda F
Antimicrob Agents Chemother; 2000 Sep; 44(9):2259-62. PubMed ID: 10952565
[TBL] [Abstract][Full Text] [Related]
16. In vitro pharmacodynamic parameters of sordarin derivatives in comparison with those of marketed compounds against Pneumocystis carinii isolated from rats.
Aviles P; Aliouat EM; Martinez A; Dei-Cas E; Herreros E; Dujardin L; Gargallo-Viola D
Antimicrob Agents Chemother; 2000 May; 44(5):1284-90. PubMed ID: 10770763
[TBL] [Abstract][Full Text] [Related]
17. Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia.
Merali S; Chin K; Del Angel L; Grady RW; Armstrong M; Clarkson AB
Antimicrob Agents Chemother; 1995 Sep; 39(9):2023-6. PubMed ID: 8540710
[TBL] [Abstract][Full Text] [Related]
18. Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329.
Schmatz DM; Powles M; McFadden DC; Pittarelli LA; Liberator PA; Anderson JW
J Protozool; 1991; 38(6):151S-153S. PubMed ID: 1818147
[TBL] [Abstract][Full Text] [Related]
19. New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat.
Schmatz DM; Powles MA; McFadden D; Nollstadt K; Bouffard FA; Dropinski JF; Liberator P; Andersen J
Antimicrob Agents Chemother; 1995 Jun; 39(6):1320-3. PubMed ID: 7574523
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of terbinafine in children.
Gupta AK; Cooper EA; Lynde CW
Dermatol Clin; 2003 Jul; 21(3):511-20. PubMed ID: 12956204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
